Concepedia

Author

Óscar Gallego

Hospital de Sant PauORCID

Also Known As

F Pascual Velasco, G. Reynes, Gallego, Oscar, O GALLEGO, O Gallego, O S Gallego, O. Gallego, O. S. Gallego, O.S. Gallego, Oscar GALLEGO

151

Publications

2.2K

Citations

24

H-Index

54

Concepts

All Affiliations

Hospital de Sant PauInstitut Català d'OncologiaInstituto de Salud Carlos IIIHospital Clínico San CarlosInstitut d'Investigació Biomédica de Bellvitge
ÓG

About

Óscar Gallego is an author at Hospital de Sant Pau specializing in medicine, oncology, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

14

15

698

2

Health Sciences

2

2

224

3

Public Health

2

2

87

4

Engineering

1

1

103

5

Biostatistics

1

1

27

Óscar Gallego

×

34

Publications

1.6K

Citations

22

H-Index

YearCitations

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

J. Guigay, Anne Aupérin, Jérôme Fayette,

The Lancet Oncology

2021

214

Phase II trial of dacomitinib, a pan–human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification

Juan Manuel Sepúlveda-Sánchez, María Ángeles Vaz Salgado, Carmen Balañá,

Neuro-Oncology

2017

119

Detoxifying Antitumoral Drugs via Nanoconjugation: The Case of Gold Nanoparticles and Cisplatin

Joan Comenge, Cármen G. Sotelo, Francisco M. Romero,

PLoS ONE

2012

103

A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01)

Carmen Balañá, María Ángeles Vaz Salgado, Juan Manuel Sepúlveda-Sánchez,

Neuro-Oncology

2020

103

Efficacy of Sequential High-Dose Doxorubicin and Ifosfamide Compared With Standard-Dose Doxorubicin in Patients With Advanced Soft Tissue Sarcoma: An Open-Label Randomized Phase II Study of the Spanish Group for Research on Sarcomas

Joan Maurel, Antonio López–Pousa, R. de las Peñas,

Journal of Clinical Oncology

2009

73

Drug resistance in patients experiencing early virological failure under a triple combination including indinavir

Óscar Gallego, Carmen de Mendoza, Maria Jesús Pérez‐Elías,

AIDS

2001

70

Prediction of Virological Response to Lopinavir/Ritonavir Using the Genotypic Inhibitory Quotient

Daniel González de Requena, Óscar Gallego, Luisa Valer,

AIDS Research and Human Retroviruses

2004

61

Predictors of Virological Response to Atazanavir in Protease Inhibitor-Experienced Patients

Ana Barrios, Ana Lucía Rendón, Óscar Gallego,

HIV Clinical Trials

2004

60

Pseudoprogression as an adverse event of glioblastoma therapy

Carmen Balañá, Jaume Capellades, Estela Pineda,

Cancer Medicine

2017

58

Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial

Carmen Balañá, R. de las Peñas, Juan Manuel Sepúlveda-Sánchez,

Journal of Neuro-Oncology

2016

55

Page 1